Vijay Pande, a general partner at a16z Bio + Health, is joined by venture partner Surya Ganguli and investing partner Bowen Liu. They dive into how AI is revolutionizing drug development, highlighting its role in identifying new targets and optimizing clinical trials. Discussions touch on the power of large datasets in advancing personalized medicine, as well as the exciting potential of using AI to merge various biological data types. Their perspectives present a captivating look at the future of health technology and research.